

MIDAS own API Product List

October 2023



Active Pharmaceutical Ingredients

API	Quality	Phase	Regulatory Status
5-Aminolevulinic acid HCl	USP /DAB / In-house (EU)	Commercial	Approved: ASMF (EMA) / US-DMF / CH-DMF (Swissmedic) / Ongoing: J-DMF Approval received by MoH of Turkey
Amfepramone HCl (Diethylpropion HCl)	In-house (EU/USA)	Commercial	Approved: ASMF/ US-DMF
Bamipine Lactate	In-house (EU)	Commercial	Approved: ASMF
Clofazimine	EP / USP	Commercial	Approved: CEP Reference Ready: US-DMF
Crotamiton	EP / USP / CP	Commercial	Approved: CEP/ US-DMF / C-DMF (China)
Doxapram HCl	EP / USP / JP	Commercial	Approved: CEP / US-DMF / J-DMF
Doxazosin mesylate	EP	Commercial	Approved: CEP
Ethacridine Lactate	EP	Commercial	Approved: CEP
Ketoprofen	EP / JP	Commercial	Approved: CEP
Levosimendan	In-house (EU)	Commercial	Approved: ASMF
Pipamperone 2HCl	In-house (EU)	Commercial	Approved: ASMF
Propofol	EP / USP	Commercial	Approved: CEP Ongoing: US-DMF / K-DMF (Korea)
Trospium Cl	EP / USP	Commercial	Approved: CEP / US-DMF
Warfarin Na	EP	Commercial	Approved: CEP
Zofenopril Ca	In-house (EU)	Commercial	Approved: ASMF

Disclaimer: No reference of a product in the list above constitutes an offer for sale or shall be construed as representing an offer for sale. In particular, the list of products above shall not be construed as promotion or advertisement for products or for the use of such products that infringe valid patents or equivalent protection rights and/or are not authorized or allowed by any applicable regulation or law.